Showing results (71-80 of 100) with videos related to
Sort By:
Pageof 10
The Lancet. Oncology|December 5, 2024
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2019
Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO)Agnes Dumas, Ines Vaz Luis, Thomas Bovagnet, et al.Plos One|October 12, 2012
Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classificationFabien Reyal, Catherine Belichard, Roman Rouzier, et al.Cancer|August 1, 2022
Coffee and tea consumption, patient-reported, and clinical outcomes in a longitudinal study of patients with breast cancerDavide Soldato, Julie Havas, Tracy E Crane, et al.British Journal of Cancer|October 21, 2025
Working conditions associated with return to work 2 years after breast cancer: insights from a cohort studyGarazi Ruiz de Azua, Idlir Licaj, Sandrine Pinto, et al.Cancer Medicine|August 21, 2023
Sustainable return to work among breast cancer survivorsGarazi Ruiz de Azua, Isabelle Kousignian, Ines Vaz-Luis, et al.European Journal of Cancer (Oxford, England : 1990)|March 26, 2022
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancerSuzette Delaloge, Sylvain Dureau, Véronique D'Hondt, et al.Breast Cancer Research and Treatment|October 23, 2021
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancerPauline Corbaux, Audrey Lardy-Cleaud, Marie Alexandre, et al.British Journal of Cancer|June 17, 2022
Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO studyJennifer L Baker, Antonio Di Meglio, Arnauld S Gbenou, et al.The Lancet. Oncology|February 20, 2025
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trialHervé Bonnefoi, Florence Lerebours, Marina Pulido, et al.Pageof 10